Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19429830 | 0.82 | DAO (0.37) | DAOKCNH2GRIN2BMPOFFAR1 | |
| SCHEMBL27542274 | 0.79 | TLR7 (0.36) | KCNH2 | |
| SCHEMBL23399240 | 0.78 | GABRA1 (0.32) | DAO | |
| SCHEMBL24040188 | 0.77 | DAO (0.34) | DAOKCNH2GRIN2BMPOFFAR1 | |
| SCHEMBL27110118 | 0.76 | GAA (0.40) | NPSR1GLSSMN1; SMN2 | |
| SCHEMBL26926613 | 0.76 | DAO (0.38) | DAOKCNH2GRIN2BMPOFFAR1 | |
| SCHEMBL2608838 | 0.76 | FFAR1 (0.39) | DAOKCNH2GRIN2BMPOFFAR1 | |
| SCHEMBL256691 | 0.76 | — | — | |
| SCHEMBL17051327 | 0.75 | PDE10A (0.35) | SMN1; SMN2 | |
| SCHEMBL14012143 | 0.75 | BCHE (0.33) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292300-A1 | DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-23 | — | — | US | disclosed |
| US-20200289456-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | SEQUOIA PHARMACEUTICALS, INC., | 2020-09-17 | — | — | US | disclosed |
| US-9884048-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884048-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170354636-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | SEQUOIA PHARMACEUTICALS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170354636-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | SEQUOIA PHARMACEUTICALS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9540354-B2 | Diamide inhibitors of cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150087676-A1 | Diamide Inhibitors of Cytochrome P450 | SEQUOIA PHARMACEUTICALS INC (US) | 2015-03-26 | — | — | US | disclosed |
| US-8906647-B2 | Diamide inhibitors of cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110098236-A1 | DIAMIDE INHIBITORS OF CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087676-A1 | Diamide Inhibitors of Cytochrome P450 | CYP2E1, CYP1A2, CYP3A43 | DAO 213/4885KCNH2 3093/4885GRIN2B 2854/4885 |
| US-20170266167-A1 | ERK INHIBITORS | MAPK1, MAPK3, MAPK6 | DAO 4224/4885KCNH2 4355/4885GRIN2B 3144/4885 |
| US-20200289456-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | HCCS, CYP2E1, CYP7A1 | DAO 1525/4885KCNH2 4309/4885GRIN2B 3816/4885 |
| US-20210292300-A1 | DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS | TLR9, TLR7, TLR8 | DAO 1724/4885KCNH2 1618/4885GRIN2B 862/4885 |
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | DAO 550/4885KCNH2 4751/4885GRIN2B 1425/4885 |
| US-20170354636-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | HCCS, CYP2E1, CYP7A1 | DAO 1525/4885KCNH2 4309/4885GRIN2B 3816/4885 |
| US-20110098236-A1 | DIAMIDE INHIBITORS OF CYTOCHROME P450 | CYP2E1, CYP1A2, CYP3A43 | DAO 213/4885KCNH2 3093/4885GRIN2B 2854/4885 |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | DAO 595/4885KCNH2 2188/4885GRIN2B 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.